中国药房2024，Vol.35Issue(9)：1145-1150,6.DOI:10.6039/j.issn.1001-0408.2024.09.21
1例头孢他啶阿维巴坦致四肢阵发性痉挛的药学监护
Pharmaceutical care for a patient with paroxysmal spasms of extremities caused by ceftazidime-avibactam
摘要
Abstract
OBJECTIVE To explore the role of clinical pharmacists in identifying paroxysmal spasms caused by drugs,and provide reference for rational drug use.METHODS Retrospective analysis was conducted on pharmaceutical care provided by clinical pharmacists for a patient with ceftazidime-avibactam(CZA-AVI)induced paroxysmal spasms.The clinical pharmacists identified,analyzed and summarized the clinical manifestations,risk factors and treatment methods of the nervous system toxicity caused by antibacterial drugs.According to the patient's clinical symptoms and test results,the clinical pharmacists recommended temporarily discontinuing the use of polymyxin B and montelukast sodium,and halving the dose of CZA-AVI.The physicians did not adopt the recommendation to halve the dose of CZA-AVI,and when the patient's neurologic toxicity did not improve,the clinical pharmacists again recommended discontinuing CZA-AVI,which was accepted by the physicians.RESULTS Clinical pharmacists analyzed the condition and checked related drugs that caused paroxysmal spasms of extremities one by one,and finally determined that CZA-AVI might be the drug that caused paroxysmal spasms of extremities in the patient.After stopping the drug,the patient's symptoms improved and was transferred to a community hospital for rehabilitation treatment.CONCLUSIONS The dose of CZA-AVI should be adjusted according to the renal function and the neurotoxicity should be guarded against,especially for patients with advanced age,renal insufficiency,and the combined use of multiple drugs related to nephrotoxicity and neurotoxicity.关键词
头孢他啶阿维巴坦/四肢阵发性痉挛/不良反应/药学监护/神经系统毒性Key words
ceftazidime-avibactam/paroxysmal spasms of extremities/adverse drug reactions/pharmaceutical care/nervous system toxicity分类
医药卫生引用本文复制引用
周佳,谭湘萍,李洁娜,邓燕红..1例头孢他啶阿维巴坦致四肢阵发性痉挛的药学监护[J].中国药房,2024,35(9):1145-1150,6.基金项目
深圳市医学重点学科项目(No.深卫健科教[2020]6号) （No.深卫健科教[2020]6号）
